Ultragenyx Pharma (RARE) Misses Q3 EPS by 28c

Ultragenyx Pharma (NASDAQ: RARE) reported Q3 EPS of ($1.96), $0.28 worse than the analyst estimate of ($1.68). Revenue for the quarter came in at $25.8 million versus the consensus estimate of $29.12 million.

• Strong Crysvita® (burosumab) Launch Continues with Approximately 1,130 Patients on Reimbursed Commercial Therapy in the United States as of the end of the Third Quarter
• UX007 (triheptanoin) NDA for Treatment of Long-chain Fatty Acid Oxidation Disorders Accepted for Review by FDA

“The U.S. launch of Crysvita continues to be strong with the number of patients on reimbursed therapy continuing to increase, which will be further supported by the recently expanded label for both pediatric and adult patients,” said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx. “The New Drug Application for UX007 is now being reviewed by FDA, and our second indication for Crysvita for tumor-induced osteomalacia will be submitted in the coming months, potentially giving us approved treatments for four different diseases in 2020.”

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• Intuitive Surgiical (ISRG) beats earnings, revenue expectations in Q1
• BayCom Corp (BCML) Misses Q1 EPS by 4c
• Southern First Bancshares, Inc. (SFST) Misses Q1 EPS by 8c